Xeris Biopharma Holdings (XERS) Earnings Date & Reports

Key Takeaways

• Xeris reported record total revenue of $107.2 million for the third quarter of 2026, up 44% year over year.
• Recorlev led the way with net revenue of $71.5 million, a 93% increase from the prior-year period.
• Net income reached $11.3 million, compared with $0.6 million a year earlier, with GAAP (Generally Accepted Accounting Principles) diluted EPS (earnings per share) of $0.06.
• Management raised full-year 2026 revenue guidance to $395 million–$405 million and lifted its 2030 revenue outlook to more than $1 billion.
• Gvoke net revenue declined 14% to $21.7 million due to a one-time gross-to-net adjustment, despite 5% prescription growth.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 77% to $30.8 million.
• For more information on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for deeper analysis.
• You can also explore Trending AI Robots to discover AI-driven trading strategies aligned with current market conditions.

Earnings Context and Why It Matters

Xeris Biopharma's third quarter 2026 report is a key checkpoint for investors tracking the company's transition into a consistently profitable, commercial-stage biopharmaceutical business. After years of operating losses, Xeris has built momentum behind Recorlev, its treatment for endogenous Cushing's syndrome, alongside the established Gvoke and Keveyis franchises. The quarter tested whether January's commercial team expansion would translate into accelerated revenue, and whether Gvoke could return to growth after a slow start to the year. With the company also advancing its XP-8121 pipeline toward a Phase 3 trial, this report offered an important read on both near-term execution and the durability of its long-term growth story.

Reported Results

Xeris delivered record results for the third quarter of 2026. Total revenue rose 44% year over year to $107.2 million, while net product revenue grew 43% to $106.3 million. Recorlev drove the performance with net revenue of $71.5 million, up 93%, reflecting record referrals and new patient starts. Keveyis generated $13.0 million, up 9%, marking a fourth consecutive quarter of year-over-year growth.

Gvoke net revenue declined to $21.7 million from $25.2 million a year earlier, pressured by a one-time $4 million gross-to-net adjustment in the Medicaid channel, even as prescription demand rose 5%. Gross margin improved to 88% from 85%, supported by favorable product mix. R&D (research and development) expenses totaled $11.1 million, while SG&A (selling, general, and administrative) expenses rose to $64.1 million.

Net income reached $11.3 million, or $0.06 per diluted share, versus $0.6 million a year ago and above the consensus estimate. Adjusted EBITDA climbed 77% to $30.8 million. Management raised full-year 2026 revenue guidance to $395 million–$405 million, and the company now projects more than $1 billion in total revenue by 2030.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors monitoring companies like Xeris Biopharma, the AI Screener can provide a structured, data-driven starting point for evaluating the broader opportunity set.

Market Reaction and Investor Sentiment

Investors responded favorably to the report, with shares advancing as attention focused on the revenue beat, the raised guidance, and the strength of the Recorlev franchise. The quarter reinforced the view that Xeris's commercial investments are beginning to yield tangible results, while the improved 2030 outlook signaled greater long-term confidence from management. Sentiment was also supported by progress on the balance sheet, including the July retirement of the company's 8.00% convertible senior notes, which eliminated roughly $34 million of debt and about $3 million in annual interest expense. The main area of investor caution centered on Gvoke's headline decline, though management framed the shortfall as a one-time adjustment against a backdrop of improving prescription trends.

Forward Outlook and Key Factors to Monitor

Following this quarter, investors will be watching whether Recorlev can sustain its momentum as the expanded commercial team matures and whether Gvoke returns to steady dollar growth once the gross-to-net adjustment clears. The company's raised 2030 target of more than $1 billion in total revenue—up from a prior outlook of $750 million—sets a higher bar that will require continued execution across all three commercial products.

The XP-8121 pipeline remains a critical longer-term catalyst. Xeris expects to initiate its pivotal Phase 3 Cornerstone study by year-end, with top-line data anticipated in late 2028 and potential launch in 2030. Investors should also monitor operating expenses, as SG&A is now expected to rise roughly $60 million in 2026, and R&D spending will likely increase further as the Phase 3 program ramps up.

Finally, newly secured intellectual property—including a Keveyis patent extending to at least 2043 and a third U.S. patent on XP-8121—adds defensibility to the portfolio. The balance between continued revenue growth, disciplined spending, and pipeline advancement will be the central narrative for Xeris in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations